Kansas City Research Institute

Kansas City Research Institute is a U.S.-based clinical research center focused on conducting Phase I-IV clinical trials. The organization specializes in gastroenterology, gastrointestinal oncology, hepatology, liver disease, and metabolic disorders including metabolic dysfunction-associated steatohepatitis, obesity, type 2 diabetes, and hyperlipidemia. Founded by gastroenterologist and hepatologist Dr. Bradley Freilich, KCRI has conducted hundreds of clinical studies for patients in the Kansas City region. In May 2024, the company was acquired by Alcanza Clinical Research, becoming part of Alcanza's investigator site network. KCRI's business is service-based rather than product-based, with offerings centered on trial execution, patient recruitment, and related clinical research activities such as FibroScan liver testing.